Background {#Sec1}
==========

Uveitis is a group of inflammatory conditions affecting the eye. It is a major cause of blindness globally, with an estimated prevalence of 38 to 114.5 per 100,000 population \[[@CR1]--[@CR3]\]. Uveitis can occur in any age, but it has a tendency to affect the working-age group, thus having a high socio-economic impact \[[@CR1]\].

The Standardisation of Uveitis Nomenclature (SUN) Working Group classifies uveitis based on the anatomical focus of inflammation: anterior (anterior chamber), intermediate (vitreous), posterior (retina and/or choroid) and panuveitis (all anatomical parts) \[[@CR4]\]. This systematic review focuses on inflammation in the anterior chamber, where inflammation causes a disruption to the normal blood-aqueous barrier, resulting in leakage of cells into the aqueous humour. These cells can be observed as floating particles in the anterior chamber (AC). An increase or decrease in the number of AC cells can be indicative of improving or worsening disease and are critical in identifying active inflammation and rationalising treatment decisions \[[@CR4]\].

Clinical examination of AC cells {#Sec2}
--------------------------------

The current standard measurement as defined by the SUN grading system is clinical examination by slit-lamp biomicroscopy, whereby a clinician aims a 1 × 1-mm slit beam through the anterior chamber and counts the number of cells visible in the lit area \[[@CR4]\]. The cell count is placed into one of six grades in the SUN grading system (Table [1](#Tab1){ref-type="table"}). Prior to the SUN grading system, a number of alternative systems existed which attempt to quantify cells in the same way; however, the SUN grading system is now the accepted standard for clinical practice and for clinical trials \[[@CR5]--[@CR9]\].Table 1The Standardisation of Uveitis Nomenclature (SUN) working group grading scheme for anterior chamber cellsGradeCells in field0\< 10.5 +1--51 +6--152 +16--253 +26--504 +\> 50Standardisation of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. \[[@CR4]\]

Optical coherence tomography {#Sec3}
----------------------------

In the last few decades, novel ophthalmic imaging techniques such as optical coherence tomography (OCT) have become widely adopted and provide new ways of quantifying disease through instrument-based measurements. OCT is fast, non-invasive and provides a quantifiable measure of ocular structure that is more sensitive and reliable than clinical estimates. Anterior segment optical coherence tomography (AS-OCT) can provide cross-sectional imaging of the AC and is able to identify cells in the anterior chamber as hyper-reflective dots. Several studies have suggested that AC cell count on OCT correlates with clinical grading \[[@CR10], [@CR11]\]. Additionally, the number of dots/cells in a given volume of aqueous humour can be counted manually or with automated software \[[@CR12]\].

Laser flare and cell photometry {#Sec4}
-------------------------------

The laser flare meter was introduced in 1988 for quantification of anterior chamber protein and cells \[[@CR13]\]. It is a fast and non-invasive technique which measures the amount of light scatter from particles as a laser beam is projected into the anterior chamber. The amount of back-scattered light is proportional to the concentration and size of proteins and cells in the aqueous humour.

Laser flare-cell photometry is primarily used in the estimation of AC flare (the hazy appearance given to the aqueous fluid by inflammatory proteinaceous leakage); however, certain models can be used for counting AC cells. Counting of cells by laser photometry is reported to be less accurate than its use in measuring flare, particularly in the extreme ends of the spectrum \[[@CR14]\].

Purpose {#Sec5}
-------

Although we are aware of two main instrument-based techniques for quantifying AC cells, it is possible that more technologies, newer generations of the same technologies or the same technologies accompanied by newer acquisition techniques and software automation are available. The aim of this systematic review is to investigate all instrument-based methods for quantifying AC cells and evaluate the correlation of these measures with clinical grading using slit-lamp examination in patients with uveitis. Where reported, we will also compare the level of reliability and repeatability for these methods to determine which yields the most reliable results. For the purposes of this review, we will refer to all instrument-based methods as 'index tests'.

Aim {#Sec6}
===

To investigate which instrument-based technologies for measuring anterior chamber cells in uveitis are available and assess their level of validation.

The following questions are proposed:Which non-invasive instrument-based tests (index tests) have the potential to measure anterior chamber cells in uveitis?What is the level of agreement between each index test and grading by clinical examination?What is the reliability and repeatability of each index test?

Methods {#Sec7}
=======

Protocol {#Sec8}
--------

This protocol is designed as per guidelines of Preferred Reporting Items for Systematic Review and Meta-Analysis Protocol (PRISMA-P) \[[@CR15]\]. The systematic review will be reported in accordance to the PRISMA guidelines \[[@CR16]\].

Systematic review registration {#Sec9}
------------------------------

Our protocol has been registered on PROSPERO (CRD42017084156) \[[@CR17]\].

Searches {#Sec10}
========

Databases {#Sec11}
---------

The relevant data for this review is likely to come from studies assessing a variety of quantitative research questions in uveitis; therefore, our search strategy will reflect the pathological finding of interest 'anterior chamber cells' and the disease context 'uveitis'. No search terms will be applied for the 'technologies/tests' to maximise sensitivity of the search. For bibliographic databases, free text and index terms (where available) will be combined for each search element. A sample search strategy for MEDLINE can be found in the [Appendix](#Sec24){ref-type="sec"}. We will search:Bibliographic databases of published studiesMEDLINE (Ovid), 1946--presentEmbase (Ovid), 1947--presentThe Cochrane library, database inception--presentCentre for Reviews and Dissemination database (Health Technology Assessments and the Database of Abstracts and Reviews of Effects), database inception - presentRegisters of clinical trials[Clinicaltrials.gov](http://clinicaltrials.gov) ([www.clinicaltrials.gov](http://www.clinicaltrials.gov))WHO International Clinical Trials Registry Platform (ICTRP portal) ([www.who.int/ictrp](http://www.who.int/ictrp))Abstract and conference proceedingsBritish library EthosProQuest ([www.proquest.com](http://www.proquest.com))Dissertations and thesesBritish Library's ZETOCConference Proceedings Citation Index (Web of Science)Grey literatureOpenGrey ([www.opengrey.eu](http://www.opengrey.eu))

No restrictions will be placed on year or language of publication. The literature search results will be entered onto EndNote × 8.2 (Clarivate Analytics, Philadelphia, PA) to facilitate removal of duplicates, study selection, recording decisions and references. References to other works will be considered for inclusion.

Selection criteria {#Sec12}
==================

Participants/population {#Sec13}
-----------------------

The populations of interest are those with evidence of anterior chamber cells and/or a diagnosis of uveitis, irrespective of active or inactive inflammation. There will be no restrictions on age, gender, ethnicity, or underlying aetiology or anatomical subtype. Studies with only healthy participants and studies on animals will not be included.

Index test {#Sec14}
----------

Included studies should describe one or more instrument-based methods for counting the number of anterior chamber (AC) cells.

Comparator {#Sec15}
----------

Included studies should use a clinical grading system (such as the SUN grading system) as a comparator.

Primary outcome {#Sec16}
---------------

The primary outcome is the correlation between index tests and the clinical grading system; the reported outcome should be a correlation coefficient for the two measures. Studies which do not report a correlation coefficient but report matched measurements for the index and reference tests can be included, and the correlation coefficient extrapolated during analysis.

Additional outcome {#Sec17}
------------------

To assess the reliability of a test, inclusion of a comparator is not required. The outcome of interest is intra/inter-observer reliability and repeatability of an index test in the same population as above.

Type of study {#Sec18}
-------------

There will be no restrictions on study design; however, evaluation of correlation between index test and clinical grading using slit-lamp examination requires both tests to be done in a cross-sectional manner. Only those studies where measurements are taken within a reasonable time point (within 24 h of each other) will be included.

Case reports involving only one subject, commentaries, opinion articles and pictorial articles will not be included.

Selection process {#Sec19}
=================

Titles and abstracts of records returned by the searches will be screened for relevance to the review, to remove obviously irrelevant studies Two independent reviewers will carry out quality assessment and reach consensus by discussion or referral to a third reviewer.

Full text of potentially relevant articles will be retrieved and assessed for inclusion in the review against the full selection criteria.

Data extraction {#Sec20}
===============

Data will be extracted from the included studies using a standardised data extraction form in Microsoft Excel (Microsoft, Washington, UK). The extraction process will be carried out by two independent reviewers with referral to a third reviewer if necessary. Information to be extracted from all studies include the following:Study characteristicsTitle, authors, publication year, journal and languageSample sizeStudy designIndex test usedManufacturer and model (including resolution and scan speed)Image acquisition settingsArea, volume and position scanned in the ACSoftware for image analysis and level of automation (manual, semi-automated or fully automated)Clinical grading system measurementsObserver (same observer or different observers)Description of grading system used, including the name of the system, number of grades and number of cells in each gradeSlit lamp settings such as area and brightness of illuminationPatients' characteristicsAge, gender and ethnicityUnderlying aetiologies (type of uveitis, anatomical subtype, aetiological classification)Active or inactive diseaseIf the study involves a therapeutic intervention: treatment details (indication, drug, dosage, route, subject pre/post-treatment status and length of follow-up)Outcomes and findingsData will be extracted in preparation for two separate analyses depending on the data reported:*Evaluation of correlation between index tests and a clinical grading system:* Studies which include AC cell measurement by both index test and a clinical grading system in the same population will be used to evaluate the level of correlation between the two tests. The correlation coefficient reported will be directly extracted. If no correlation coefficient is reported, we will extract index and reference test measurements, providing they are matched, and calculate the correlation coefficient. If the two measurements are not matched, we will contact the authors for matched measurements.*Evaluation of reliability and repeatability of an index test:* Studies which report intra- and inter-observer reliability for a study will be analysed separately for assessment of repeatability. The reported kappa values will be extracted for intra-observer reliability and inter-observer reliability.Cross-sectional measurements may be nested within longitudinal studies whose primary aims are not to compare performance or correlation between two tests. In this situation, measurements at each time point should be extracted and analysed as individual cross-sectional comparisonsResults of sub-analyses and sensitivity testing for uveitis subtype (aetiological and anatomical) and disease activity (active versus inactive disease)

Quality assessment {#Sec21}
==================

Quality assessment of all included studies will be based on elements from the Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS2) \[[@CR18]\]. Assessment will be carried out at the study level. Two independent reviewers will carry out quality assessment and refer to a third reviewer if needed.

It is anticipated that a small number of studies will meet the inclusion criteria, with many of which being early proof-of-concept studies with a high risk of bias. Therefore, the risk of bias assessment and quality of evidence will be reported but will not influence data synthesis.

For studies assessing the correlation between an index and reference test, the following four risk of bias domains will be rated as low, high or unclear \[[@CR18]\]:Selection of participantsSelection of participants with different degrees of disease severity should be justified in the context of assessing the full spectrum of disease, as opposed to any prior knowledge of how disease severity may affect test performance. As severe inflammation (i.e. grade 4+) is less prevalent than mild inflammation (i.e. + 0.5), a random selection of participants would invariably result in more participants with milder disease than participants with severe disease.Exclusion of participants should be justified in the context of interference with index test measurement (i.e. corneal opacities may prevent visualisation of AC structures behind it, or the presence of AC pigment may appear like AC cells but is caused by a different pathological process).Index testsWe will consider whether index test acquisition and analysis parameters were determined a priori and consistent for all participants in the study.If analysis of index tests were done manually (i.e. manual counting of AC cells in an image), we will consider whether the observer was blinded to the clinical AC cell grading, and vice versa.Reference testWe will consider whether assessment using the clinical grading system in each study was standardised, i.e. performed by the same clinician, consistent slit-lamp settings such as brightness of illumination and ambient settings such as room lighting.Flow and timingOrder of tests: The order of tests does not affect the interpretability of results if the observer of one test is blinded to the results of the other test.

For studies assessing the reliability of a single index test, the same assessment should be done for selection of participants and index tests as above. Additional considerations should be given for:Intra-observer reliability studies: the conditions under which index test repeatability was performed should be reported and kept consistent (i.e. room lighting, slit lamp beam intensity).Inter-observer reliability studies: as well as the points relating to intra-observer reliability, any differences between observers (such as seniority and experience) should be reported and accounted for.

Data synthesis {#Sec22}
==============

Data synthesis will be divided into analysis for the two outcomes: correlation with reference test and reliability of index test. For each outcome, a narrative synthesis of tabulated evidence will be conducted and supported with a meta-analysis where possible.Evaluation of correlation between index and reference testThese studies will be grouped by type of technology (i.e. OCT, laser flare cell photometry).For each type of technology, we are expecting small numbers of studies; therefore, we will analyse different platforms, generations or manufacturers of the same technology together.Studies will then be grouped by comparator (i.e. different clinical grading systems).If the data allows, correlation coefficients between each index test versus reference test will be compared and pooled for meta-analysis.Evaluation of reliability and repeatability of an index testThese studies will also be grouped by type of technology, as described above.Intra-observer and inter-observer reliability will be analysed separately for each technology. If the data allows, reliability measure (i.e. Kappa values) will be compared and pooled for meta-analysis.

Assessment of clinical and methodological homogeneity will determine whether studies are sufficiently similar to allow for appropriate data pooling by meta-analysis. Heterogeneity across studies in each meta-analysis will be quantified using the *I*^*2*^ statistic. Irrespective of the ability to appropriately undertake any meta-analyses, data will be reported narratively across all studies for each grouping.

We will perform sensitivity analyses if there is significant heterogeneity between studies. If data permits, we will consider subgroup analyses for population groups (i.e. age, gender and ethnicity), anatomical subtype of uveitis and aetiological subtype. It is anticipated that only a small number of studies will be relevant to the inclusion criteria, and this may limit our ability to carry out meaningful subgroup analyses.

Discussion {#Sec23}
==========

The assessment of uveitis is complex: firstly, because uveitis describes a heterogeneous group of diseases with significant variations between different anatomical and disease-specific subtypes, and secondly, because many clinical measures in ophthalmology are based on visual function (namely visual acuity), which are subjective to the patient and do not always reflect active inflammation. Treatment for anterior uveitis, namely topical steroids, carry side effects such as increased risk of glaucoma and accelerated onset of cataract. The ability to reliably measure ocular inflammation in uveitis is important for rationalising treatment in clinical practice and assessing disease outcome in clinical trials.

Whilst the consensus Standardisation of Uveitis Nomenclature meeting of 2005 was a significant effort towards defining a systematic method in assessing uveitic inflammation, it is recognised that its reliance on clinical examination remains subjective, unreliable and poorly sensitive. A number of factors can affect the examiner's ability to see AC cells including the slit lamp optics, the degree of illumination, and the observer's skills \[[@CR19]\]. The problem exists that clinical grading through examination is error-prone and is therefore susceptible to intra-observer and inter-observer variability \[[@CR19], [@CR20]\]. Clinical grading systems also typically classify levels of severity into stepwise grades, in a non-continuous and non-linear fashion, with a wider range of cell counts in the higher grading groups (i.e. 26--50 cells in field for grade 3+ and \> 50 cells in field for 4+) than lower grading groups \[[@CR4]\]. According to the SUN criteria, "improved activity", or a decrease in inflammation, requires a two-step improvement or resolution to grade 0. However, a much larger reduction of AC cell count is required in higher grades of inflammation (i.e. 4+ to 2+ requires 50+ cells decreasing to 16--25 cells) than lower grades (i.e. 2+ to 0.5+ requires 16--25 cells decreasing to \< 1 cells). This non-linear grading scale may not be able to detect small changes, especially within higher grades of inflammation, allowing potentially clinically meaningful changes to go undetected. In clinical trials, this could result in new therapies being deemed as failure, despite having a clinically significant improvement.

Instrument-based technologies such as the laser flare-cell photometer and OCT have shown potential for assessing anterior chamber cells in several studies. These instrument-based measures are less operator-dependent and carry advantages such as objectivity. However, their performance in these domains has not been compared in a systematic way. The field of ophthalmic imaging is continuing to expand rapidly; therefore, it is timely to undertake a systematic review to examine the evidence for instrument-based measures of intraocular inflammation.

This systematic review will explore the range of technologies available for measuring AC cells to estimate their level of reliability and correlation with clinical grading systems. The findings from this review would contribute to the process of validating instrument-based methods for guiding treatment decisions in clinical care and for measuring outcome in uveitis clinical trials.

Appendix {#Sec24}
========

Table 2MEDLINE sample search strategy1Exp Uveitis/2Uveiti\*. Ti, ab.31 or 24Anterior chamber. Ti, ab.5Aqueous humour. Ti, ab.6Aqueous humor. Ti, ab.74 or 5 or 68Cell\*. Ti, ab.93 and 7 and 8

AC

:   Anterior chamber

MEDLINE

:   Medical Literature Analysis and Retrieval System Online

OCT

:   Optical Coherence Tomography

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta-Analysis

QUADAS2

:   Quality Assessment of Diagnostic Accuracy Studies

SUN

:   Standardisation of Uveitis Nomenclature
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